Tokuhiro E, Dean H J, Friesen H G, Rudman D
J Clin Endocrinol Metab. 1984 Mar;58(3):549-54. doi: 10.1210/jcem-58-3-549.
The biological activity of GH in serum from 10 adult volunteers, 6 children with normal stature, and 26 children with growth retardation was assessed using the Nb2 rat lymphoma cell bioassay and the IM-9 human lymphocyte receptor modulation assay. The bioassay/RIA ratios for both bioassays varied widely but the range of ratios found in the normal stature adults and children was not different than that found in the group of children with growth retardation, which included 4 children with a presumptive diagnosis of bioinactive GH. We conclude that the use of these two bioassays is a valid approach to the assessment of the bioactivity of the circulating molecular forms of GH and that a large number of children with disorders of growth can be screened to identify patients with bioinactive GH.
使用Nb2大鼠淋巴瘤细胞生物测定法和IM-9人淋巴细胞受体调节测定法,评估了10名成年志愿者、6名身材正常儿童以及26名生长发育迟缓儿童血清中生长激素(GH)的生物活性。两种生物测定法的生物测定/放射免疫分析(RIA)比值差异很大,但身材正常的成年人和儿童中所发现的比值范围,与生长发育迟缓儿童组(其中包括4名初步诊断为生物活性GH缺乏的儿童)并无不同。我们得出结论,使用这两种生物测定法是评估循环中GH分子形式生物活性的有效方法,并且可以对大量生长障碍儿童进行筛查,以识别生物活性GH缺乏的患者。